Pediatr Infect Vaccine.  2018 Apr;25(1):35-44. 10.14776/piv.2018.25.1.35.

Immunogenicity and Safety of Inactivated Influenza Vaccine in Healthy Korean Children and Adolescent

Affiliations
  • 1Department of Pediatrics, Korea University Ansan Hospital, Korea University College of Medicine, Ansan, the Republic of Korea. byelhana@korea.ac.kr
  • 2Department of Pediatrics, Gyeonggi Provincial Medical Center Icheon Hospital, Icheon, the Republic of Korea.

Abstract

PURPOSE
This study aimed to evaluate the immunogenicity and safety of a trivalent inactivated influenza vaccine (TIV) among healthy Korean children and adolescents.
METHODS
From October to December 2008, 65 healthy patients aged 6 months to 18 years who visited Korea University Ansan Hospital for influenza vaccination were enrolled in this study. We measured the hemagglutinin inhibition antibody titers at baseline and 30 days after vaccinating enrollees with split influenza vaccine and calculated the seroprotection rates, geometric mean titers, and seroconversion rates. Local and systemic adverse events were assessed after vaccination.
RESULTS
The seroprotection rates against all three viral strains (A/H1N1, A/H3N2, B) were 87.7%, 89.2%, and 89.2% (≥70%), respectively; seroconversion rates were 44.6%, 73.8%, and 63.1% (≥40%), respectively; and seroconversion factors were 4.5, 8.4, and 10.5 (>2.5), respectively. The TIV immunogenicity was acceptable according to the CPMP (Committee for Proprietary Medicinal Products) criteria. Although 48 patients (73.8%) reported one or more adverse events, no severe adverse events such as anaphylaxis and convulsion were observed. Forty-two patients (64.6%) reported a local skin reaction, including redness (29.2%), pain (43.1%), or swelling (41.5%) of the injected site, and 26 (40.0%) reported a systemic reaction: fatigue (23.1%), myalgia (20.0%), headache (10.8%), arthralgia (10.8%), chills (9.2%), or fever (7.7%).
CONCLUSIONS
This study shows that the immunogenicity of the TIV vaccine is acceptable. As there were no serious adverse events aside from local reactions and mild systemic reactions, this vaccine can be safely used among healthy Korean children and adolescents.

Keyword

Influenza vaccines; mmunogenicity, vaccine; Safety

MeSH Terms

Adolescent*
Anaphylaxis
Arthralgia
Child*
Chills
Fatigue
Fever
Gyeonggi-do
Headache
Hemagglutinins
Humans
Influenza Vaccines*
Influenza, Human*
Korea
Myalgia
Seizures
Seroconversion
Skin
Vaccination
Hemagglutinins
Influenza Vaccines
Full Text Links
  • PIV
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
    DB Error: unknown error